Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Tuesday

Krystal Biotech (NASDAQ:KRYS - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of $1.35 per share and revenue of $98.66 million for the quarter.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same quarter last year, the company posted $0.30 EPS. Krystal Biotech's revenue for the quarter was up 116.4% on a year-over-year basis. On average, analysts expect Krystal Biotech to post $6 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Krystal Biotech Stock Up 1.0 %

NASDAQ:KRYS opened at $169.73 on Tuesday. Krystal Biotech has a 1-year low of $141.72 and a 1-year high of $219.34. The firm has a market capitalization of $4.90 billion, a price-to-earnings ratio of 56.77 and a beta of 0.75. The stock has a fifty day simple moving average of $176.24 and a 200 day simple moving average of $171.50.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on KRYS shares. Jefferies Financial Group started coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective for the company. Citigroup upped their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Chardan Capital increased their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. HC Wainwright increased their price target on shares of Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a research note on Monday. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Krystal Biotech presently has a consensus rating of "Buy" and an average target price of $222.71.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.